A probably new entity of metabolic error of folic acid was described of an infant whose clinical and biochemical characteristics were: 1) mental retarda tion and a marked dilatation of cerebral ventricles, 2) abnormally high serum L. casei folate activity, 3) abnormally high levels of folate precursor in erythrocytes, and 4) a marked rise in reticulocyte count by an exogenous folate supplementation.
A probably new entity of metabolic error of folic acid was described of an infant whose clinical and biochemical characteristics were: 1) mental retarda tion and a marked dilatation of cerebral ventricles, 2) abnormally high serum L. casei folate activity, 3) abnormally high levels of folate precursor in erythrocytes, and 4) a marked rise in reticulocyte count by an exogenous folate supplementation.
The results of investigation on tetrahydrofolate -dependent enzymes of liver specimens revealed a decreased activity of N5 methyltetrahydrofolate transferase of our own patient.
It seems therefore likely that an impaired utilization of N5 methyltetrahy drofolate and its precursor in tissues due to a decreased activity of N5 methyl tetrahydrofolate transferase led to an abnormal accumulation of N5 methyl tetrahydrofolate and its precursor in serum and erythrocytes, and that trapping of folate compounds at an N5 methyltetrahydrofolate level caused a functional deficiency of folates with sequence of development of a megaloblastic change in the bone marrow and of an impaired purine biosynthesis of the brain with a marked dilatation of cerebral ventricles. 
Laboratory findings
The results of liver function tests revealed no abnormality except for a slight increase in serum alkaline phosphatase (cf. Table 1) .
Serum levels of sodium and potassium were found to be within normal limits . Total lipids were 628 mg/100 ml, and phospholipids 237 mg/100 ml, both being within normal limits. Total cholesterol was 205 mg/100 ml, being slightly higher than normal values.
Total protein in serum had been slightly decreased at the time of the admission, and soon after that time it increased to normal levels (cf. Table 2 ). Urinalyses for sugar, protein and acetone were negative. The FeCl3 test was negative. Thin layer chromatographic analysis for urinary amino acids revealed no abnormality. Chromosomal analysis revealed a normal pattern in number and configuration. Coombs' tests (direct and indirect) were negative.
D-Xylose absorption test: 0.5 g/kg of D-xylose dissolved in 100 ml of water was given; and 5 , hours' urine specimens following the dosage were collected and assayed for -xylose excreted. The result revealed that 22.3% of the oral dose were excreted into the 5 hours' urine, indicating no disturbance in the intestinal absorption of D-xylose.1
Intestinal absorption of fat: When placed on a diet containing 22-24.8 g of fat per day, the fecal fat excretion was found to be ranging from 2.2 to 3.0 g per day, indicating no abnormality in digestion and absorption'`. of the dietary fat (March [20] [21] [22] 1965) .
I 131-T3 resin sponge uptake was found to be 30%, being within normal range .
Electroencephalograms recorded on April 17, and June 10, 1965 revealed hypsarrhythmia (cf. Fig. 1 ).
Pneumoencephalograms revealed a marked dilatation of lateral ventricles with Evans' ratio of 0.47 on the right side and of 0.53 on the left side and a dilatation of the third ventricle of 16 mm in diameter (cf. Fig. 2 ).
Fundoscopic examination revealed no abnormality. Methylmalonate excretion in urine was examined paperchromatographically with Barness et al.'s method3, but it was not detected on repeated examinations.
Urinary excretion of aminoimidazole carboxamide (AICA) was found to be 0.03 mg/kg/day and 2.56 mg/kg/day before and after an oral dose of 20 mg/kg of AICA chloride, respectively. These values were considered to be an increased excretion of AICA.4
Serum folate levels were determined in the same way as described by Herbert6 except that the culture media for Lactobacillus casei and Streptococcus faecalis were prepared according to Spray's report.5 As shown in Table 3 , the serum folate activity was found to remain at abnormally high levels throughout the period of her hospitalization (cf. Table 3 ). In our present study, the erythrocyte folate activity was determined in the following two ways :
(a) Folate activity of erythrocytes without preceding incubation of hemo lysates with plasma. About five ml of blood were taken into a heparinized syringe and erythrocytes were separated by centrifugation, then washed three times with its 4 or 5 volumes of cold 0.14 M NaCl solution containing 0.5% sodium ascor bate. Two ml of ion free water were added to 0.5 ml of the washed erythrocytes: To 0.5 ml of the hemolysate 4.5 ml of 0.05 M potassium phosphate buffer of pH 6.1 containing 200 mg% of ascorbic acid were added. The mixture was autoclaved at 120°C for ten minutes. After centrifugation the clear supernatant was used for folate assay in the same way as in the serum folate assay. 5, 6 (b) Folate activity of erythrocytes after preceding incubation with plasma. This was done in the same way as described by Cooper and Lowenstein. 10 The erythrocyte folate activity was found to be markedly increased in our own patient especially when the folate was assayed on the erythrocyte lysate after incubation with plasma (cf. Table 5 ). Urinary excretion of formiminoglutamic acid (FIGLU) following an oral dose of L-histidine monohydrochloride, 0.33 g/kg of bodyweight: Urinary FIGLU, estimated with Tabor and Wyngarden's method,9 was found to be within the normal limit at the early period of her admission (April, 1965), but it tended to increase dur ing -the later period of vitamin Bit therapy (October , 1965), especially after withdrawal of the vitamin B12 administration (Feb., 1966) . This excessive excre tion of urinary FIGLU was abolished after intramuscular administrations of pteroyl glutamic acid in a dose of 5 mg per day for consecutive seven days (July, 1966) (cf. Table 6 ). Peripheral blood pictures and bone marrow findings Macrocytic anemia with megaloblastoid cells and ringed sideroblasts in the bone marrow were found at the time of her admission. Because of a relatively low level of serum vitamin B12, a vitamin B12 therapy with massive doses was done over a considerably long period (from July, 1966 to January, 1967) but its effect upon hematologic findings seemed to be hardly evaluated with precision because folic acid was given orally or intravenously on several occasions during the period of vitamin B12 therapy (cf. Table 7) .
Hematologic response to folic acid was investigated on three occasions: the first, consisted of 5 mg of pteroylglutamic acid per day, intramuscularly for con secutive 7 days, July 1966; the second, 15 mg of pteroylglutamic acid per day, intramuscularly, for consecutive 16 days, February 1967; and the third, 0.75 mg of pteroylglutamic acid per day, intramuscularly, for consecutive 10 days, April 1967.
A marked rise in reticulocyte counts was followed by the first and second trials with folic acid administration, but a slight increase in reticulocyte counts was observed in the third. There was no increase in red cell count after the folic acid administration (cf. Table 7 ).
An intramuscular administration of pyridoxal phosphate, 20 mg per day for consecutive 5 days, May 1967, could bring about a rise in reticulocyte count but not in erythrocyte count (cf. Table 7) .
Megaloblastoid cells and giant metamyelocytes were found in the bone marrow smears persistently throughout the period of observation notwithstanding the count MCP, MCH, reticulocyte counts and megaloblastoid cells of our own patient et al. Table 7 . Continued therapy with either vitamin B12 or folic acid (cf. Table 7 ).
Activities of tetrahydrofolate-dependent enzymes of the liver or of erythrocytes
The activities of formiminotransferase, cyclohydrolase, serine-hydroxymethylase and N5 methyltetrahydrofolate-transferase were assayed on liver specimens obtained by surgical or needle biopsy from our own patient and control patients without hepatic disease.
As regards formate-activating enzyme and N5,10 methylenetetrahydrofolate dehydrogenase, their activity was estimated on erythrocyte lysates. et al. Formate-activating enzyme activity of erythrocyte lysate
The enzyme assay was carried out in the same way as described by Bertino et al.12 except that ATP-Na was used in place of ATP-K. The erythrocyte lysates used were of hemoglobin concentrations ranging from 4.1 g/100 m] to 5.3 g/100 ml. The results, as shown in Table 13 , showed that the formate-activating enzyme activity of erythrocyte lysate did not decrease in our own patient as compared with that of controls (cf. Table 13 ).
N5,10 methylenetetrahydrofolate dehydrogenase activity of erythrocyte lysate
The enzyme assay was carried out in the same way as described by Bertino et al." except that the incubation time of the reaction mixture was 15 minutes in place of 30 minutes adopted by the original method. The erythrocyte lysates were made so as to be of hemoglobin concentration of 4.6 g/100 ml-6.0 g/100 ml. The results, as shown in Table 14 , revealed that the N5,10 methylenetetrahy drofolate dehydrogenase activity of erythrocyte lysate did not differ between our own patient and controls (cf. Table 14) . DISCUSSION 1) An accumulation of N5 methyltetrahydrofolate and its precursors in erythrocytes probably due to a decreased activity of N5 methyltetrahydrofolate transferase Hoffbrand et al. 15 reported that red cell folate levels of 40 healthy subjects ranged from 160 to 640 my per ml of packed red cells and that red cell folate levels were subnormal (ranging from 7 to 143 my per ml) in 40 patients with megaloblastic anemia.
Cooper and Lowenstein10 examined the erythrocyte folate L. casei activity of healthy subjects after incubation of erythrocyte lysate with plasma and found that the mean erythrocyte folate was 422 my per ml of packed red cells for 24 normal subjects.
As regards red cell folate activity determined after an incubation with plasma, it was markedly increased in our own patient as compared with that reported by Hoffbrand et al.75 and by Cooper and Lowenstein.10 This finding indicated that there might be an abnormal accumulation of folate-precursors in erythrocytes of our own patient.
Furthermore it was found that the folate activity of erythrocytes, which was determined without the preceding incubation of the lysate with plasma, was also remarkably higher in our own patient than in controls examined in the present study. This indicated a, possible accumulation of N5 methyltetrahydrofolate itself16 in the erythrocytes of our own patient (cf. Table 5 ).
An accumulation of both N5 methyltetrahydrofolate and its precursors in mature erythrocytes suggested an impaired utilization of N5 methyltetrahydrofolate, consequently of its precursors, which might be due to a decreased activity of N5 methyltetrahydrofolate transfe.rase of erythroid cells maturing in the bone marrow, because folate compounds did not pass out of or enter into the circulating red cells.10,17
2) An increased output of urinary FIGLU and its relation to administration of large doses of vitamin B12 Urinary excretion of FIGLU following an oral dose of L-histidine was examined repeatedly throughout her hospitalization, and was found to be not increased at the early stage of the hospitalization. But it tended to increase during, and especially immediately after withdrawal of administration of large doses of vitamin 13, (cf. Table 6 ).
As regards the relationship between vitamin B12 and N5 methyltetrahydrofolate t.ransferase, Buchanan et al. 18 reported that methyltetrahydrofolate-homocysteine transferase purified from the hog liver was identical to that from the bacterial system in substrate specificity and cofactor requirements, and that the cobamide content was found to be proportional to the methyltetrahydrofolate transferase activity throughout the purification.
In 1964 Dickerman et (11.14 investigated the role of vitamin B,, in methionine biosynthesis in chick livers and reported that: 1) nutritional deficiency of cyan-B12 (5,6-dimethylbenzimidazolyl-cobamide cyanide) in young chicks led to a marked reduction of N5 methvltetrahvdrofola.te and methyl-B12 (5,6-dimethvlbenzimidazol cobamide methyl)-transferase activities; replenishment with cyan-B,2, deoxyadeno syl-B12, and methyl B,, resulted in partial restoration of both activities; and 2) cyano-B12, deoxyadenosyl-B12, methyl B12 and reduced form of cyano-B,2 all stimulated the methyltetrahydrofolate transferase reaction aerobically and, to a lesser extent. anaerobically.
In view of these reports above quoted it would be expected that a diminished excretion of urinary FIGLU following oral (lose of histidine might be induced by large doses of vitamin B12, because vitamin B12 administration may stimulate the N5 methyltetrahydrofolate transferase reaction, consequently leading to enhancement of tetrahydrofolate available for the formiminotransferase reaction. In contrast to this, in our own patient, urinary FIGLU was increased during later stage of vitamin B,, therapy.
One possibility of explanation for this was that tetrahydrofolate was utilized in an increased amount for the hematopoiesis which was stimulated by large doses of vitamin B12.
This possibility seemed likely in view of the results of Dinning and Young19 From these findings, it seemed unlikely that megaloblastic anemia of our own patient was included into childhood pernicious anemia. 23 An early onset of megaloblastic anemia and the absence of proteinuria also afforded an evidence against Grasbeck et al.'s syndrome (selective vitamin B12 malabsorption and proteinuria in young people). 24 The absence of urinary excretion of orotic acid or of uracil excluded megalo blastic anemia due to orotic aciduria25 or uraciluria. 26 Vitamin B6 deficiency anemia was also unlikely, because abnormal tryptophan metabolites were not found in urine of our patient following an oral dose of tryptophan.
A considerable reticulocyte response to intramuscular administration of pyri doxal phosphate (20 mg per day, for consecutive 5 days) showed a possibility of vitamin B6 responsive anemia in our own patient.
The reason for this reticulocyte response caused by vitamin B6 administration remains obscure, but there is a possibility that massive doses of vitamin B6 exert some accelerating effect upon serine-hydroxymethylase, consequently result ing in an increased yielding of N5,10 methylenetetrahydrofolate which is utilized for hematopoiesis.
It was quite curious to notice that, in spite of the presence of hyperfolic acidemia, oral (March, 1965) and intramuscular (July, 1966, and February, 1967 ) administra tion of folic acid caused a hematologic response with a decrease in MCV with a preceding rise in reticulocyte counts. This suggested that folic acid supplemented exogenously could be utilized effectively for hematopoiesis of our own patients. In other words, in our own patient with decreased activity in N5 methyltetrahydrofolate transferase, it may be assumed that folate compounds accumulated at N5 methyl tetrahydrofolate level soon after folic acid was given exogenously, thus leading to make them unavailable for other pathways, then resulting in a functional deficiency27 of hematologically active folate compounds. 4) Mental retardation and dilatation of cerebral ventricles of our own patient As described in the foregoing, a decreased activity of N5 methyltetrahydrofolate transferase was demonstrated in the liver of our own patient. This suggested a possible shortage of tetrahydrofolate produced via the N5 methyltetrahydrofolate transferase reaction. Even though both the formate-activating enzyme and N5,10 methylenetetrahydrofolate dehydrogenase of erythrocytes were found to be increased in their activity, an increased urinary excretion of AICA following an oral dose of AICA afforded an evidence supporting a possible shortage of N10 formyl tetrahydrofolate.
It may be therefore assumed that in a similar way as in cases with formimino transferase deficiency28,29 an impaired purine biosynthesis in the brain might have resulted from a shortage of N10 formyltetrahydrofolate due to a decreased activity of N5 methyltetrahydrofolate transferase in our own patient.
